Huobi HTX expanded its contract offerings on October 19 by adding three new USDT perpetual markets: LULU/USDT, DNA/USDT, and Q/USDT. These contracts allow traders to use leverage ranging from 1x to 20x, enabling both long and short positions. Alongside the launch, a trading contest runs until October 22, where participants can win a share of 1 billion HTX tokens by trading eligible contracts and meeting event criteria. This expansion follows the exchange's earlier addition of six USDT perpetual contracts on October 8, also offering up to 20x leverage, signaling Huobi HTX's push to broaden its derivatives market.
Huobi HTX's new perpetual contracts come as 41 of 50 major cryptocurrencies on Pluang rose today. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 19, 2026 15:02 WIB: SOL (Solana) traded at Rp1.898.186 with a 1-day change of +2.51% and a typical hold time of 71 days, LINK (Chainlink) at Rp220.262 with +2.33%, and ENJ (Enjin Coin) at Rp491 with a -2.15% change and a typical hold time of 105 days.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
